Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DMJR has to refinace AGAIN in March. Lucky Them!
These guys along with IMSC managment are sucking the cookie dry.
DMJR and IMSC managment drinking Dom Perignon for New Years.
Stockholders lucky to afford a beer.
Happy New Year
Gio
Van
My humblest apologies as I, a life long runer and weight lifter,
knows what it takes to fully enjoy life. Being fit is essential.
I will be sending you a check as I now feel you have put at least the same amount of effort into your financial well being.
I thought you were a lazy hustler who needed to sell subscriptions to make a living. Laughing at myself as I was 1000% wrong.
Gio
"I am not even going to lie"
lol and Thanks
Gio
How cheap?
Thanks Gio
"J&J's ortho clinical diagnostics unit makes blood-screening equipment and laboratory blood tests. It also makes tests that can identify a patient's blood type and screen for viruses such as HIV and hepatitis C.
The unit is a small player in a market led by larger rivals such as Roche Holding AG (ROG.VX), Siemens AG (SIE.DE), Abbott Laboratories (ABT) and Danaher."
This seems very reasonable. Judge will most likly grant.
Thanks to Nolerman:
DEFENDANTS’ NOTICE OF MOTION TO STAY; MEMORANDUM OF POINTS AND AUTHORITIES IN SUPPORT OF DEFENDANTS’ MOTION TO STAY
Date: January 17, 2014 Time: 9:00 a.m.
Dept: 10
Judge: Honorable Susan Illston Date Filed: October 3, 2012
Trial Date: None Set
Case No. 12-cv-06293 SI
"Please take notice that on January 17, 2014 at 9 am, or as soon thereafter as counsel may be heard in the above-captioned Court, Defendants LinkedIn Corp. (“LinkedIn”) and Facebook, Inc. (“Facebook) (collectively “Defendants”) will, and hereby do, respectfully move for a stay.
Defendants seek a temporary stay of these coordinated actions pending the Supreme Court’s decision in Alice Corp. v. CLS Bank Int’l, which is expected approximately five months after this motion is set for hearing.
I. INTRODUCTION
Last Friday, the Supreme Court granted certiorari in Alice Corp. v. CLS Bank Int’l to answer “[w]hether claims to computer-implemented inventions—including claims to systems and machines, processes, and items of manufacture—are directed to patent-eligible subject matter within the meaning of 35 U.S.C. § 101 as interpreted by this Court?” No. 13-298, cert. granted (U.S. Dec. 6, 2013). The Court’s decision—which is expected by June 2014—will carry sweeping implications for the patents Bascom asserts in this case. Not only are those patents directed to computer-implemented inventions, but they claim abstract ideas whose patentability is highly questionable at best.
Under the current schedule, the Court, as well as the parties, will expend considerable resources over the coming months which may quickly prove to have been wasted once the Supreme Court rules. A tutorial and Markman hearing are set for late February or early March.1 Thus, this Court may issue its Markman ruling, resolving numerous disputed claim constructions, just weeks before the Supreme Court definitively declares Bascom’s patents invalid, and the parties may incur very significant unnecessary costs during this period as well.
Under these circumstances, the Court should stay this action pending the Supreme Court’s decision. Bascom concedes, as it must, that “[t]he Supreme Court’s decision in Alice is likely to clarify the current uncertainty surrounding software patentability.” Dkt. 121 at 3. A stay will be brief—approximately five months from when the instant motion is set for hearing. Further, a stay will not prejudice Bascom. Bascom is a non-practicing entity and shell company with no legitimate business operations. Moreover, Bascom waited over six years before suing LinkedIn and Facebook, and can hardly complain about a stay of a few months that may conserve an enormous amount of the Court’s and parties’ resources.
For these reasons, and as explained more fully below, Defendants respectfully ask the Court to temporarily stay these coordinated actions pending the Supreme Court’s decision in Alice Corp."
We need to see the response from Bascom and a subsequent order.
All or nothing on the Alice Corp Decision.
See you later boys
"Total 55.6 shares after warrants and this should be it going forward!"
Nice
Gio
I hope I am wrong.
I hope they can start putting up some serious numbers.
I am now from Missouri.
Gio
Is Russia a sale? Or a loan of the equipment?
Reads to me as a loan!
Gio
DECN: <<Berman hopes to announce a first private-label deal in January that would move hundreds of thousands of boxes of strips each year. >>
http://www.decisiondiagnostics.com/documents/20131217dealarticle.html
DECN: <<Berman hopes to announce a first private-label deal in January that would move hundreds of thousands of boxes of strips each year. >>
50%/50% split after legel fees and expenses?
"Finally, the company announced that it is in discussions with Platinum to fund the prosecution of the company's Anti-trust lawsuit against J&J/Lifescan."
Gio
Mr. S Thank you
I also have a team of lawyers who looked this over for me and then they all invested;O)
They think this is over but do acknowledge that their is no end to arrogance @ J&J.
Can they get a supreme interested, I say 10 to 1 against.
Gio
Decision Diagnostics Receives Mandate From U.S. Court of Appeals for the Federal Circuit in the Long Running Dispute With J&J DivisionFont size: A | A | A
9:15 AM ET 12/17/13 | Marketwire
RELATED QUOTES
9:44 AM ET 12/17/13
Symbol Last % Chg
DECN
0.65 -4.43%
JNJ
91.18 -0.21%
Real time quote.
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip(TM), the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that on December 11, 2013 the United States Court of Appeals for the Federal Circuit issued its Mandate, making its November 4, 2013 ruling final. Plaintiffs Lifescan Scotland, Ltd, and Lifescan, Inc., divisions of Johnson & Johnson failed to appeal the initial Circuit Court ruling during the statutory period of time allowed, although they still have time to appeal to the U.S. Supreme Court.
Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, "We are elated that U.S. Court of Appeals for the Federal Circuit has issued this mandate, making final the current appeal portion of our long standing battle with J&J Lifescan. With the instructions in the ruling that the Circuit Court issued to the trial court in early November, we feel that we can now put what is left of the patent infringement case to the side and pursue our own anti-trust and false advertising claims against J&J/Lifescan."
Forward-Looking Statements:
lol
Thanks for the laugh.
Gio
he was probably a despondent IMSC shareholder..
1.80 to 82 cents
-Sarcasm for the humor impaired-
Gio
And look at the stock price zoom....
Thanks Glenn
Gio
this ain`t chess my friend
real $$$$
They are building a new website, it should redirect you to a Gemstrip website but it is not connecting at this time.
Gio
someone who agrees just sold 60,000 shares
ALERT: Temporary Trading Halt in Effect for OTC Markets Group
I was pointing out the stock price is burying IMSC
that goofball on yahoo is proven correct
and IMSC "investors" took the pipe.
Gio
My father owned one of the largest cig vending machine
companies in the Northeast. I like the idea of XXII and bought.
The manipulation and control of nicotine and tar in
the design and manufacture of cigarettes: A scentific
Perspective
http://legacy-dc.ucsf.edu/documentStore/d/q/m/dqm29h00/Sdqm29h00.pdf
OSI has the money and juice to be corrupt and still avoid
bad things happening to them.
They will be buying old and new politicians to grease their
corrupt practices.
no body wants old swab tech
Gio
Do not lose faith sully knows something we do not.
Gio
Then they subtracted the BIG CONTRACT that never came to fruition.
This will be a butt ugly Quarter
Gio
Does Smiths or Morpho Have any machines that qualify under this standard:
"Although thy are looking for non radioactive sources, they will consider radioactive sources that require no oversight, per the Q&A."
___________________________
Advanced Trace Detection Instrumentation and Methodologies/DHS S&T
05/16/13 Notifications for award negotiations.
07/14 - 09/14 - Contract Awards
https://www.fbo.gov/index?s=opportunity&mode=form&tab=core&id=525a5d413645fd0238a0277c3b022a94&_cview=0
Although thy are looking for non radioactive sources, they will consider radioactive sources that require no oversight, per the Q&A.
This is based on the draft BAA. The final BAA should be published mid to late Jan.
sal
that is not a trade
call your broker and ask for an explanation.
Gio
Another hurdle for IMSC
Bureaucrats listen to people who schmooze them
===========================
The reason for the cancelled contract is simple
Smiths told the TSA too
www.smithsdetection.com/en/press-events/press-releases/121-october-1/376.html#.UqH_LPRDvX4
J&J Article From Forbes
Take a gamble premon. Forbes is backing you up.
Forbes is not some rag touting this stock, it is a very valuable member of the investing community since 1917.
"But challenges continue to confront J&J on several fronts, including a U.S. Court of Appeals ruling in late October 2013 that rejected its lawsuit against the marketing of a product that competed with its glucose testing strip. The court ruled that Shasta Genstrip Technologies, a subsidiary of Decision Diagnostics (DECN), is within its rights to sell its own glucose testing strip, and that any decision allowing a JNJ unit, Lifescan, to block sales of the competing Shasta product would unfairly eliminate competition.
The Shasta product is an alternative diagnostic that’s substantially equivalent to JNJ’s lucrative glucose monitoring system meter and diagnostic, called LifesScan Ultra, of which JNJ has sold nearly $5 billion worldwide in almost a decade.
JNJ is estimated to be making over $2 billion in profits from its glucose monitoring business alone, so it is understandable why it’s seeking legal action to block the sale of the competing product. Fortunately for JNJ, it could just opt to gobble up Decision Diagnostics and acquire the company’s rising FDA-approved glucose testing strip called Genstrip. JNJ could eventually merge Decision Diagnostics with its Janssen Pharmaceuticals division."
http://www.forbes.com/sites/genemarcial/2013/12/05/healthcare-giants-stock-remains-attractive-despite-major-setbacks/
too many shares out to move the stock price
do a reverse stock split and get some new blood into this tired old stock promotion.
Thanks Glenn
Gio
Great Article Go DECN
Another Forbes Article
Thanks stckdytrdr
Gio
Healthcare Giant's Stock Remains Attractive Despite Major Setbacks
Comment Now Follow Comments
As the stock market continues to climb to all-time highs, one of the major sectors that remains highly attractive is healthcare. And one Big Pharma that continues to be an attractive play – despite being buffeted by recent forceful headwinds — is Johnson & Johnson (JNJ).
Probably no other major pharmaceutical company has faced the monumental setbacks that Johnson & Johnson (JNJ) had to confront in the past couple of years, including an agreement in November 2013 to pay $2.5 billion to settle thousands of lawsuits for faulty hip replacement implants that led to injuries and additional surgeries to about 8,000 patients. And J&J will also pay $2.2 billion as part of a settlement with the Dept. of Justice over the alleged improper marketing of an anti-psychotic drug, Risperdal, for the treatment of dementia from March 2002 to December 2003.
Yet J&J’s stock has remained resilient, continuing to trade near its 52-week high of $95.47 a share. The stock closed at $93.88 on Dec. 4, 2013, way up from its 52-week low of $70 a share a year ago. True, the stock market’s robust bull market rally this year has helped J&J, but Wall Street believes it’s one of the best Big Pharma plays, so institutional investors remain upbeat on the prospects of this pharmaceutical giant that describes itself as the most diverse and the largest healthcare company in the world.
Indeed, JNJ’s record in the industry is almost unmatched: Revenues last year jumped to $67.2 billion, (up from 2011’s $65 billion), generating a very strong free cash flow of $12.5 billion that reflects a consistently sterling performance with 29 years of consecutive adjusted earnings increases, and 51 years of consecutive dividend increases.
“Johnson & Johnson stands alone as a leader across the major healthcare-industries,” says Morningstar in a recent research report. “The company maintains a diverse revenue base, a robust research pipeline, and exceptional cash flow generation that together create a wide economic moat,” it added.
One big driver of its growth is undoubtedly its fresh product pipeline — and constant renewal of new products, with about 25% of sales coming from products introduced in the last five years.
“We view JNJ as uniquely situated with unmatched depth and breadth in growing global health care markets, with solid positions in drugs, medical devices, and consumer products,” says Herman Saftlas, analyst at S&P Capital IQ. Rating the stock a buy, he has a 12-month price target for the stock of $102 a share, based on his estimated 2014 earnings of $5.80 a share, up from $5.47 that Saftlas projects for 2013. J&J earned $3.86 a share in 2012.
New drugs such as Xarelto, Zytiga, and Invokana should lead the growth in J&J’s pharmaceuticals unit, which accounted for 38% of 2012 sales, he adds.
The latest J&J new drug that the Food and Drug Administration approved in November is for the treatment of chronic hepatitis C infections. The drug, a protease inhibitor, blocks a protein needed by the virus to replicate. The drug, named as Olysio, is aimed at eliminating hepatitis C, the most common form of the liver-destroying virus. Olysio is the third drug that the FDA has approved to combat hepatitis C, a blood-borne disease believed responsible for some 15,000 deaths every year.
J&J is also developing a novel therapy for Alzheimer in collaborating with Evotec, which has a proprietary database on the disease. The agreement involves J&J investing in Evotec’s research and developmental efforts and making payments of up to $145 million on reaching certain milestones.
But challenges continue to confront J&J on several fronts, including a U.S. Court of Appeals ruling in late October 2013 that rejected its lawsuit against the marketing of a product that competed with its glucose testing strip. The court ruled that Shasta Genstrip Technologies, a subsidiary of Decision Diagnostics (DECN), is within its rights to sell its own glucose testing strip, and that any decision allowing a JNJ unit, Lifescan, to block sales of the competing Shasta product would unfairly eliminate competition.
The Shasta product is an alternative diagnostic that’s substantially equivalent to JNJ’s lucrative glucose monitoring system meter and diagnostic, called LifesScan Ultra, of which JNJ has sold nearly $5 billion worldwide in almost a decade.
JNJ is estimated to be making over $2 billion in profits from its glucose monitoring business alone, so it is understandable why it’s seeking legal action to block the sale of the competing product. Fortunately for JNJ, it could just opt to gobble up Decision Diagnostics and acquire the company’s rising FDA-approved glucose testing strip called Genstrip. JNJ could eventually merge Decision Diagnostics with its Janssen Pharmaceuticals division.
Forbes Magazine is hardly a pump and Dump.
Forbes article was on March 13,2013.
Second Forbes Article was on Sept 11,2013.
Those are the dates pump&dumpcon has listed as
DECN pumps.
If Forbes is a pump,
Please have more Forbes Articles.
Gio
You Mean Pray! Dear Lord ,Please restore my reputation
for getting anyone involved with IMSC. If only I kept my mouth shut.
We have the same problem sully.
I at least always reserve the right to be 100% wrong when I pick a stock and in this case I was.
Gio
New info like the throw up numbers at the end of this Q.
12 Biz days left till the end of the year. Oppps Lots of partays as both holidaze fall on weds.
Gio
Do not waste your time speaking to Glenn.
What can he say that is already not publicly disclosed.
SEC laws. Pesky things.
Gio
DECN New Lower price Genstrip Cost $9.95
Gio
Wait till the inexpensive shares fall by 50%
you will be very grateful:O)
Gio
If Glenn says it and you hear it correctly, you will turn out to be wrong as Glenn slides away. What happened to that $3.5 million contract that Glenn told us about on the CC?
forgetaboutit he said 3 weeks later? Correct?
Gio